The US company has said it is launching the Phase III trials in the first half of this year after Phase I talks with the US ...

Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...

Ketamine disrupts abnormal brain activity, offering long-term relief for Parkinson’s dyskinesia in early clinical trials.

Medtronic’s BrainSense aDBS is a therapy intended to improve the quality of life for individuals living with Parkinson’s disease.

Bemdaneprocel will be studied in a sham-surgery controlled, double-blind trial that is expected to start in the first half of ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Medtronic (NYSE: MDT) announced today that it received CE mark approval for its BrainSense adaptive deep brain stimulation ...

AskBio begins patient randomizing in phase II gene therapy trial for Parkinson’s disease: Berlin, Germany Wednesday, January 15, 2025, 14:00 Hrs [IST] AskBio Inc. (AskBio), a ge ...

Mytos’ technology will automate the manufacturing of neuronal precursors for Aspen's autologous cell therapy for the brain disorder.

While hand tremors are one of the most common symptoms of Parkinson’s disease it isn’t the only one There are other signs ...

aDBS transmits electrical signals to the brain to disrupt certain unwanted movements for patients living with Parkinson’s disease. With the technology, patients receive real-time therapy that ...